G Sachs released a research report saying that BEONE MEDICINES (06160.HK) -6.200 (-2.719%) Short selling $94.18M; Ratio 28.104% recorded product sales revenue of USD1.68 billion in 2Q, up 29% YoY and slightly above the broker's and market expectations. Core product Brukinsa continued to deliver strong global sales performance, rising 31% YoY to USD1.25 billion, further consolidating its leadership position in the global BTK inhibitor market with a market share of 38%. Its US market sales increased 31% YoY to USD893 million, above the broker's forecast of USD822 million.

In response to the strong 2Q performance, management again raised its full-year 2026 guidance. Total revenue guidance was lifted from USD6.3 billion-USD6.5 billion to USD6.6 billion-USD6.8 billion; GAAP operating profit guidance was raised from USD750 million-USD850 million to USD1 billion-USD1.1 billion; non-GAAP operating profit guidance was increased from USD1.45 billion-USD1.55 billion to USD1.7 billion-USD1.8 billion. G Sachs also raised its 2026-2028 EPS forecasts and increased the US stock TP for BeOne Medicines Ltd. (ONC.US) from USD414.46 to USD441.3, while maintaining the Buy rating. (gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-24 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)